PDCD1 and cancer: Blocking various regions of these immune checkpoint axes by therapeutic antibodies, which is referred to as immune checkpoint blockade (ICB), represents a novel and promising strategy that has proven its worth in clinical practice for different types of cancer, at least for CTLA-4 and PD-1 blockades [54].